Affinity Asset Advisors’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Affinity Asset Advisors’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-400,726	Closed	-$1.08M	–	101
2023 Q3	$1.08M	Buy	400,726 +160,482	+67%	+$629K	0.3%	57
2023 Q2	$2.24M	Buy	240,244 +142,023	+145%	+$1.4M	0.78%	36
2023 Q1	$872K	Buy	+98,221	New	+$964K	0.29%	57

Other funds holding THRX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Affinity Asset Advisors's THRX Position: Q4 2023 in Review

Affinity Asset Advisors sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q4 2023, closing a stake of 400,726 shares — an estimated $1.08M sold.

Affinity Asset Advisors first reported a position in THRX in Q1 2023 and held it in 3 quarters. The position peaked at $2.24M in Q2 2023. 70 funds tracked by Wall St. Rank hold THRX as of Q4 2023.

Affinity Asset Advisors reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Affinity Asset Advisors sold 400,726 Theseus Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $1.08M.
Affinity Asset Advisors first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 3 quarters.
Affinity Asset Advisors's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $2.24M in Q2 2023.
70 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Affinity Asset Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.